Rhythm Pharmaceuticals Культура компании

Dr. Keith Michael Gottesdiener, M.D., has been the Chief Executive Officer of Motus Therapeutics, Inc. and Rhythm Holding Company, LLC since October 2011. Dr. Gottesdiener has been the Chief Executive Officer of Rhythm Pharmaceuticals Inc. since October 2011 and has been its President since August 2017. He serves as an Executive Director of Rhythm Metabolic, Inc. Prior to Rhythm, he served as Vice President and Late-Stage Therapeutic Group Leader at Merck & Co., Inc., with responsibility for pivotal trials of Merck's products in all therapeutic areas and served as the Head of Early-Stage Clinical Development Programs. Over a 16-year career at Merck, he was responsible for more than 40 major clinical programs and products, including the approval of Gardasil(TM) (HPV vaccine) and the more recent FDA approval of Victrelis(TM) (HCV protease inhibitor). From 2006 to 2011, he was a Leader of Merck's late clinical development organization, first overseeing the development of Merck's infectious diseases and vaccine products through pivotal trials, registration and life cycle management, including GardasilTM (HPV Vaccine), RotateqTM (rotavirus vaccine), ZostavaxTM (zoster vaccine) and IsentressTM (HIV integrase inhibitor), among others. From 2009 to 2011, he served as Merck's Vice President of Clinical Sciences and Therapeutic Area Group Leader. He has been Director of Intercept Pharmaceuticals, Inc. since July 19, 2016. He served as the Chairman at Rhythm Pharmaceuticals, Inc. until April 2017 and has been its Director since October 2011. Dr. Gottesdiener served as the Chairman of Motus Therapeutics, Inc. and serves as its Director. He served as the Chairman of the Board of Rhythm Holding Company, LLC until April 2017 and has been its Director since October 2011. After his fellowship, he did Postdoctoral Research in the Laboratory of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor. In 1986, he joined the faculty as an Assistant Professor at Columbia University, started an independent research laboratory with NIH RO-1 funding, focusing on gene transcription and was Associate Clinical Professor of Medicine at the time he left to enter Merck in 1995. He completed his residency and fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs. Dr. Gottesdiener received an A.B. from Harvard College and an M.D. from the University of Pennsylvania.

Ms. Nithya Desikan has been Chief Commercial Officer at Rhythm Holding Company, LLC since August 01, 2017 and Rhythm Pharmaceuticals, Inc. since July 2017. Ms. Desikan is a seasoned biotechnology executive, with over 15 years of experience commercializing new therapies in domestic and global markets. Previously, Ms. Desikan worked at Biogen Inc., where she served most recently as Vice President and Asset Executive, from September 2016 to July 2017, overseeing global profit and loss account for TECFIDERA??? and supporting the product's position as the #1 prescribed oral therapy in multiple sclerosis and from November 2015 to September 2016, building a team to support the Biogen pipeline for the clinical development of inflammatory bowel disease. Prior to that, Ms. Desikan held the role of Vice President and Program Executive from September 2014 to November 2015, where she led Biogen's Hematology business, now the Biogen spin-off, Bioverativ, to drive the growth of ALPROLIX??? and ELOCTATE??? and the development of multiple preclinical assets. Before that, from February 2012 to September 2014, Ms. Desikan built the strategy to support the U.S. launch of ALPROLIX, Biogen's first entrant into the orphan hemophilia market. Before joining Biogen Inc., Ms. Desikan spent 12 years at Johnson & Johnson in the United States and China, supporting brands including: XARELTO???, LEVAQUIN???, TOPAMAX???, ULTRACET???, NUCYNTA???, NUCYNTA???ER and VELCADE???. Ms. Desikan holds a B.S. in Material Science Engineering, with honors, from the University of Florida.

Dr. Fred T. Fiedorek, M.D., has been the Chief Medical Officer at Rhythm Pharmaceuticals, Inc. (also known as MOTUS THERAPEUTICS, INC.) since October 2014. Dr. Fiedorek joined Rhythm after nearly 14 years at Bristol-Myers Squibb (BMS). He served as Senior Vice President, Head of Cardiovascular (CV) and Metabolic Development at Bristol-Myers Squibb (BMS), where he led Phase 2 through Phase 4 global development for these therapeutic areas. Under his leadership, several new medicines achieved successful marketing authorization, including Onglyza??? (saxagliptin), Farxiga??? (dapagliflozin), Eliquis??? (apixaban), Myalept??? (metreleptin), Bydureon??? Dual Chamber Pen and Glucovance??? (metformin/glyburide). While at BMS, Dr. Fiedorek also previously co-led exploratory development, helping to transition compounds from discovery stage to proof-of-concept patient trials. He has extensive drug development experience across many therapeutic areas, ranging from early development through Phase 4 and commercial launch. Dr. Fiedorek has particular expertise in diabetes, metabolic disorders and cardiovascular disease. Prior to joining BMS, Dr. Fiedorek held positions of increasing responsibility at Glaxo-Wellcome in Research Triangle Park (RTP), and was International Project Leader for a Phase 3 metabolic drug development program prior to his move to BMS. Dr. Fiedorek co-directed the Clinical Science Committee charged with providing scientific, regulatory and biostatistical review of Phase 1 through Phase 4 clinical trials; he was a member of the Medical Review Group charged with oversight of potential emerging safety signals from marketed medicines or compounds in development; and he participated in joint development committees for BMS alliances with Astra-Zeneca, Pfizer, Otsuka, KAI Pharmaceuticals, Solvay and Merck. He also served on the faculties at Washington University School of Medicine in St. Louis and the University of North Carolina in Chapel Hill School of Medicine, including an adjunct clinical appointment while at Glaxo-Wellcome in RTP. He completed residency and fellowship training in Internal Medicine and Endocrinology & Metabolism at Washington University in St. Louis, including post-doctoral research on the genetics of animal models of diabetes and obesity. Dr. Fiedorek received his B.A. from Yale University and his M.D. from Harvard Medical School.

Monica Fay serves as the Senior Vice President, Medical Affairs of Rhythm Pharmaceuticals Inc.. Monica started at Rhythm Pharmaceuticals Inc. in September of 2018. Monica currently resides in Greater Boston Area.

Jim Murray serves as the Vice President Clinical Operations of Rhythm Pharmaceuticals Inc.. Jim started at Rhythm Pharmaceuticals Inc. in March of 2017. Jim currently resides in Greater Boston Area.

Alastair Garfield serves as the Executive Director of R&D and Translation Medicine of Rhythm Pharmaceuticals Inc.. Alastair started at Rhythm Pharmaceuticals Inc. in September of 2017. Alastair currently resides in Greater Boston Area.

Ilia Ichetovkin serves as the Vice President, Diagnostic Strategies of Rhythm Pharmaceuticals Inc.. Ilia started at Rhythm Pharmaceuticals Inc. in June of 2018. Ilia currently resides in Greater New York City Area.

Irene Aquino serves as the Vice President, Patient Engagement and Advocacy of Rhythm Pharmaceuticals Inc.. Irene started at Rhythm Pharmaceuticals Inc. in October of 2017. Irene currently resides in Greater Boston Area.

Lawrence Bressler serves as the Vice President, Global Launch Lead (Rare Genetic Diseases of Obesity) of Rhythm Pharmaceuticals Inc.. Lawrence started at Rhythm Pharmaceuticals Inc. in October of 2017. Lawrence currently resides in Greater Boston Area.

Patrick Kleyn serves as the Vice President, Translational R&D and Alliances of Rhythm Pharmaceuticals Inc.. Patrick started at Rhythm Pharmaceuticals Inc. in May of 2018. Patrick currently resides in Greater Boston Area.